Ascletis Signs Up with CR Pharma to Distribute Novel HCV Treatment

Ascletis BioScience of Beijing has signed a strategic cooperation agreement with CR Pharmaceutical Commercial Group to launch Ganovo® (danoprevir). Ganovo, a direct-acting anti-viral agent, is Ascletis' first approved product and the first direct-acting anti-viral HCV treatment approved in China. The approval was announced earlier this month. In May, Ascletis became the first China pharma to apply for a Hong Kong IPO under new rules allowing pre-revenue pharmas to stage their initial public offerings on the exchange. The IPO is expected later this year. More details....

Stock Symbol: (HK:3320)

Share this with colleagues:

Original Article: Ascletis Signs Up with CR Pharma to Distribute Novel HCV Treatment

More From BioPortfolio on "Ascletis Signs Up with CR Pharma to Distribute Novel HCV Treatment"